Clinical Trial Update: BBO-11818 in Adult Subjects With KRAS Mutant Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update for BBO-11818 in adults with KRAS-mutant cancers, currently recruiting across several KRAS-driven solid tumors including non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• BBO-11818

Snippet

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Conditions: Non-Small Cell Lung Cancer, NSCLC | Phase 1 | Status: RECRUITING